{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:24:52Z","timestamp":1787765092541,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the effect of prostaglandin analogs (PGA) against other glaucoma medications (non-PGA) on the intraocular pressure (IOP) outcomes of combined trabeculectomy with phacoemulsification, and the conjunctival cell profile in persons with primary open-angle (POAG) and pseudoexfoliation glaucoma (PXFG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted among 116 patients with POAG or PXFG on glaucoma medications for a minimum of 3 months undergoing glaucoma triple procedure. Patients were divided into two groups (PGA and non-PGA) based on preoperative exposure to PGA. IOP outcomes were assessed for up to 2 years. Conjunctival biopsy specimens were obtained at the time of surgery, and histopathological analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-two patients were in the PGA group, 67 were in the non-PGA group, and seven were lost to follow-up. The non-PGA group had lesser mean postoperative IOP and needed fewer postoperative medications compared to the PGA group in all visits up to 2 years. The non-PGA group had better complete success rate (50.7% vs. 14.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Kaplan\u2013Meier survival estimates showed a significant difference in cumulative complete success rate between non-PGA (67%) and PGA (26%) by 24 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The Cox proportional model showed the type of drug to be significantly associated with surgical failure. Histopathological analysis revealed that the PGA group had higher numbers for each type of inflammatory cell (except mast cells) compared to the non-PGA group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients on PGA are likely to have a higher postoperative IOP and may need more medications for IOP control after a glaucoma triple procedure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2317_23","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:00:55Z","timestamp":1704708055000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Outcome of combined trabeculectomy with cataract surgery in patients on prostaglandin analogs and aqueous suppressants"],"prefix":"10.4103","volume":"72","author":[{"given":"PR","family":"Aswin","sequence":"first","affiliation":[{"name":"Department of Retina and Vitreous, Aravind Eye Hospital, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neethu","family":"Mohan","sequence":"additional","affiliation":[{"name":"Department of Glaucoma Aravind Eye Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balagiri","family":"Sundar","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvin Kurian","family":"Ponnat","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbaiah R","family":"Krishnadas","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Schehlein","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, The Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00055735-200304000-00006","article-title":"Collaborative normal tension glaucoma study","volume":"14","author":"Anderson","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00055735-200404000-00008","article-title":"Factors for progression and glaucoma treatment: The early manifest glaucoma trial","volume":"15","author":"Leske","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-20260504","first-page":"741","article-title":"Clinical utility and differential effects of prostaglandin analogues in the management of raised intraocular pressure and ocular hypertension","volume":"4","author":"Lee","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0161-6420(89)32888-0","article-title":"Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon\u2019s capsule in glaucomatous patients","volume":"96","author":"Sherwood","year":"1989","journal-title":"Ophthalmology"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","article-title":"Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF00166608","article-title":"Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: An immunohistochemical and ultrastructural study","volume":"233","author":"Nuzzi","year":"1995","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1076\/0271-3683(200002)2021-DFT085","article-title":"Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells","volume":"20","author":"de Saint Jean","year":"2000","journal-title":"Curr Eye Res"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1167\/iovs.03-1067","article-title":"Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: An ex vivo and in vitro study","volume":"45","author":"Pisella","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20260504","first-page":"35","article-title":"Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication","volume":"48","author":"Nenciu","year":"2004","journal-title":"Oftalmologia"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1442-9071.2003.00760.x","article-title":"Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients","volume":"32","author":"Do\u011fan","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1167\/iovs.04-1331","article-title":"In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells","volume":"46","author":"Guenoun","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajo.2006.02.056","article-title":"Effects of topical antiglaucoma application on conjunctival impression cytology specimens","volume":"142","author":"Hong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1111\/j.1442-9071.2011.02591.x","article-title":"Severe vernal keratoconjunctivitis requiring trabeculectomy with mitomycin C for corticosteroid-induced glaucoma","volume":"40","author":"Ang","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"244.","DOI":"10.1186\/s12886-020-01518-6","article-title":"Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: A cross-sectional study using anterior segment optical coherence tomography","volume":"20","author":"Gozawa","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1590\/S0004-27492007000600005","article-title":"Conjunctival changes induced by prostaglandin analogues and timolol maleate: A histomorphometric study","volume":"70","author":"Russ","year":"2007","journal-title":"Arq Bras Oftalmol"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"22.","DOI":"10.1186\/1869-5760-3-22","article-title":"Conjunctival changes and inflammatory aspects in rabbits\u2019 conjunctivas induced by fixed combinations of prostaglandin analogues and timolol maleate","volume":"3","author":"de Faria","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/1060028014548569","article-title":"Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension","volume":"48","author":"Lin","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"e0181550.","DOI":"10.1371\/journal.pone.0181550","article-title":"Effects of pre-surgical administration of prostaglandin analogues on the outcome of trabeculectomy","volume":"12","author":"Miki","year":"2017","journal-title":"PLoS One"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/IJG.0000000000001168","article-title":"Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment","volume":"28","author":"Tiedemann","year":"2019","journal-title":"J Glaucoma"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10384-012-0219-3","article-title":"Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost","volume":"57","author":"Sakata","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1527-3466.2005.tb00168.x","article-title":"Bimatoprost: Mechanism of ocular surface hyperemia associated with topical therapy","volume":"23","author":"Chen","year":"2005","journal-title":"Cardiovasc Drug Rev"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.6.1.45","article-title":"The side effects of the prostaglandin analogues","volume":"6","author":"Holl\u00f3","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"R28-20260504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/eye.2013.304","article-title":"Bimatoprost 0.01% vs bimatoprost 0.03%: A 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients","volume":"28","author":"Figus","year":"2014","journal-title":"Eye (Lond)"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/bjo.77.9.590","article-title":"Adverse effects of topical antiglaucomatous medications on the conjunctiva","volume":"77","author":"Broadway","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","article-title":"Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies","volume":"106","author":"Baudouin","year":"1999","journal-title":"Ophthalmology"},{"key":"R31-20260504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bjo.2008.140186","article-title":"Effect of latanoprost and timolol on the histopathology of the human conjunctiva","volume":"93","author":"Terai","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R32-20260504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coph.2012.10.002","article-title":"Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma","volume":"13","author":"Mastropasqua","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"R33-20260504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/IJG.0b013e31825af67d","article-title":"Preservative exposure and surgical outcomes in glaucoma patients: The PESO study","volume":"22","author":"Boimer","year":"2013","journal-title":"J Glaucoma"},{"key":"R34-20260504","first-page":"786","article-title":"Glaucoma triple procedures: Efficacy of intraocular pressure control and visual outcome","volume":"21","author":"Longstaff","year":"1990","journal-title":"Ophthalmic Surg"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2317_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:21Z","timestamp":1787763681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2317_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2317_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"2023-08-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}